Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor
- PMID: 8174986
- PMCID: PMC1374797
- DOI: 10.1136/gut.35.4.490
Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor
Abstract
Short term effects of indomethacin on intestinal permeability were studied on a model of rat isolated vascularly perfused terminal ileum. The objectives of this study were (a) to assess the effects of indomethacin on intestinal permeability and histology; (b) to assess the effects of prostaglandins, leukotrienes, and platelet activating factor (PAF) on the same parameters; (c) to evaluate the role of these inflammation mediators on indomethacin induced permeability modifications. Intravascular administration of 1.25 and 2.5 mM indomethacin induced a significant increase of 51Cr-EDTA transfer rate. Histological analysis showed only mucosal oedema. Pretreatment with 16,16 dimethyl-prostaglandin E2 did not reverse these changes. Intravascular administration of PAF, leukotrienes B4 and D4 provoked a significant rise in 51Cr-EDTA transfer rate and intraluminal protein leakage, with an intense vascocongestion of the mucosal capillaries. These changes were completely prevented by perfusion of the respective specific antagonists (BN52021 for PAF, LY255,583 for leukotriene B4 and MK571 for leukotriene D4). None of these three antagonists, however, or MK886, a selective 5'-lipo-oxygenase inhibitor, could reverse the indomethacin induced permeability changes. Indomethacin induced increased intestinal permeability at these high concentrations does not seem to be a result of changed prostanoid or PAF metabolism. Alternative mechanisms of the initial damage of non-steroid anti-inflammatory drugs should be sought.
Similar articles
-
Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart.Br J Pharmacol. 1991 Dec;104(4):933-7. doi: 10.1111/j.1476-5381.1991.tb12529.x. Br J Pharmacol. 1991. PMID: 1810604 Free PMC article.
-
Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart.Br J Pharmacol. 1991 May;103(1):1097-102. doi: 10.1111/j.1476-5381.1991.tb12306.x. Br J Pharmacol. 1991. PMID: 1652337 Free PMC article.
-
Inhibition by leukotriene inhibitors, and calcium and platelet-activating factor antagonists, of acute gastric and intestinal damage in arthritic rats and in cholinomimetic-treated mice.J Pharm Pharmacol. 1999 Mar;51(3):331-9. doi: 10.1211/0022357991772330. J Pharm Pharmacol. 1999. PMID: 10344635
-
Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.Lab Invest. 1985 Jun;52(6):617-30. Lab Invest. 1985. PMID: 3925239
-
Interactions of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions.Braz J Med Biol Res. 1987;20(5):487-94. Braz J Med Biol Res. 1987. PMID: 2838117 Review.
Cited by
-
Glycomacropeptide Ameliorates Indomethacin-Induced Enteropathy in Rats by Modifying Intestinal Inflammation and Oxidative Stress.Molecules. 2020 May 18;25(10):2351. doi: 10.3390/molecules25102351. Molecules. 2020. PMID: 32443501 Free PMC article.
-
Do eicosanoids cause colonic dysfunction in experimental E coli O157:H7 (EHEC) infection?Gut. 2000 Jun;46(6):806-12. doi: 10.1136/gut.46.6.806. Gut. 2000. PMID: 10807892 Free PMC article.
-
Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.PLoS One. 2015 Mar 20;10(3):e0120802. doi: 10.1371/journal.pone.0120802. eCollection 2015. PLoS One. 2015. PMID: 25793535 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources